Table 2. Characteristics of identified plasma peptide in the participants.
Peak | Amino acid sequence | Peak identity | Total (n=1890) |
m/z 2044.75 | K.VFDEFKPLVEEPQNLIK.Q | Albumin | 105.3 (40.0-160.1) |
m/z 2065.31 | D.APRIKKIVQKKLAGDESAD.- | Pro-Platelet basic protein | 35.3 (14.2-75.1) |
m/z 2487.01 | S.NSRDDGNSVFPAKASATGAGPAAAEK.R | Hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 | 26.1 (16.7-42.1) |
m/z 3428.10 | K.YWSQQIEESTTVVTTQSAEVGAAETTLTELR.R | Keratin 18 | 60.4 (24.3-113.5) |
m/z 2883.99 | L.LPVLESFKVSFLSALEEYTKKLNTQ.- | Apolipoprotein A-I | 36.4 (19.5-59.2) |
m/z 1076.14 | E.GDFLAEGGGVR.G | Fibrinogen alpha chain | 30.2 (20.6-41.8) |
m/z 3060.13 | K.SSSYSKQ(+.98)FTSSTSYNRGDSTFESKSYK.M | Fibrinogen alpha chain | 73.6 (33.3-135.6) |
m/z 1120.39 | T.HRIHWESAS.L | Complement C3 | 18.5 (13.1-25.7) |
m/z 2190.59 | G.SPMYSIITPNILRLESEET.M | Complement C3 | 45.7 (26.2-80.4) |
m/z 1052.53 | K.SHALQLNNR.Q | Complement C4-A | 20.6 (13.7-29.9) |
m/z 1898.21 | S.STGRNGFKSHALQLNNR.Q | Complement C4-A | 24.3 (14.8-56.8) |
m/z 1607.84 | P.KC(+57.02)KEMQNSLN(+.98)NDK.N | Breast cancer type 2 susceptibility protein | 19.0 (9.97-38.8) |
m/z 2211.86 | V.YRLPPLRKGEVLPLPEAN(+.98)F.P | Histidine-rich glycoprotein | 38.1 (20.0-80.8) |
Data were presented as median together with interquartile range. Peptide content in human plasma is measured in intensity.